Multimodality tumor imaging targeting integrin alphavbeta3
Weibo Cai1, Sanjiv Sam Gambhir, Xiaoyuan Chen
1Stanford University School of Medicine, Stanford, CA 94305-5484 , USA.
Abstract:
The cell adhesion molecule integrin alphavbeta3 is an important player in the process of tumor angiogenesis and metastasis. Antibodies, peptides, peptidomimetics, and small molecule antagonists against integrin alphavbeta3 have been shown to induce endothelial apoptosis, to inhibit tumor angiogenesis, and to increase endothelial permeability. The ability to quantitatively image integrin alphavbeta3 expression in vivo in a noninvasive manner may shed new light into the mechanism of angiogenesis and antiangiogenic treatment efficacy based on integrin antagonism. Tumor integrin expression imaging will also aid in lesion detection, patient stratification, new anti-integrin drug development/validation, as well as treatment monitoring and optimization. This review summarizes the recent advances in multimodality imaging of tumor integrin alphavbeta3 expression using magnetic resonance imaging (MRI), ultrasound, near-infrared (NIR) fluorescence, single photon emission computed tomography (SPECT), and positron emission tomography (PET).
Insights
Noninvasive imaging of integrin alphavbeta3 expression in tumors can reveal insights into angiogenesis and anti-angiogenic therapy. This approach aids in early cancer detection and drug development.
Area of Science:
- Oncology
- Molecular Imaging
- Biochemistry
Background:
- Integrin alphavbeta3 is crucial for tumor angiogenesis and metastasis.
- Targeting integrin alphavbeta3 with antagonists can inhibit tumor growth and increase vascular permeability.
Purpose of the Study:
- To review advances in multimodality imaging of tumor integrin alphavbeta3 expression.
- To highlight the potential of in vivo imaging for understanding angiogenesis and anti-angiogenic therapy.
Main Methods:
- Review of recent literature on imaging techniques.
- Focus on magnetic resonance imaging (MRI), ultrasound, near-infrared (NIR) fluorescence, single photon emission computed tomography (SPECT), and positron emission tomography (PET).
Main Results:
- Multimodality imaging offers quantitative assessment of integrin alphavbeta3 expression in vivo.
- Imaging can aid in lesion detection, patient stratification, and treatment monitoring.
Conclusions:
- Noninvasive imaging of integrin alphavbeta3 is valuable for cancer research and clinical applications.
- This technology supports the development and validation of anti-integrin drugs and personalized cancer therapy.
